Article
Factors that predict response of patients with hepatitis C virus infection to boceprevir.
Gastroenterology - 1 Sept 2012
Poordad Fred, Bronowicki Jean-Pierre, Gordon Stuart C, Zeuzem Stefan, Jacobson Ira M, Sulkowski Mark S, Poynard Thierry, Morgan Timothy R, Molony Cliona, Pedicone Lisa D, Sings Heather L, Burroughs Margaret H, Sniukiene Vilma, Boparai Navdeep, Goteti Venkata S, Brass Clifford A, Albrecht Janice K, Bacon Bruce R
Abstract excerpt
BACKGROUND & AIMS: Little is known about factors associated with a sustained virologic response (SVR) among patients with hepatitis C virus (HCV) infection to treatment with protease inhibitors. METHODS: Previously untreated patients (from the Serine Protease Inhibitor Therapy 2 [SPRINT-2] trial) and those who did not respond to prior therapy (from the Retreatment with HCV Serine Protease Inhibitor Boceprevir and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.